Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ARC101 |
| Synonyms | |
| Therapy Description |
ARC101 is a bispecific antibody targeting CLDN6 on tumor cells and CD3 on T-cells, which potentially induces antitumor activity (Cancer Res (2025) 85 (8_Supplement_1): 7325). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ARC101 | ARC 101|ARC-101 | CD3 Antibody 119 CLDN6 Antibody 10 | ARC101 is a bispecific antibody targeting CLDN6 on tumor cells and CD3 on T-cells, which potentially induces antitumor activity (Cancer Res (2025) 85 (8_Supplement_1): 7325). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06672185 | Phase I | ARC101 | ARC101 in Advanced Solid Tumors | Recruiting | USA | ISR | CAN | AUS | 0 |